ライフサイエンスコーパス: transplant recipient

1 onor-derived C. auris transmission in a lung transplant recipient.

2 munological follow up of a cohort of 55 lung transplant recipients.

3 body responses to prevent organ rejection in transplant recipients.

4 the highest standardized incidence ratios in transplant recipients.

5 nvasive detection of AMR in pediatric kidney transplant recipients.

6 treatment of urologic malignancies in kidney transplant recipients.

7 lant recipients and is universal among islet transplant recipients.

8 ortant in the outpatient follow-up of kidney transplant recipients.

9 d safety parameters in pediatric solid organ transplant recipients.

10 redictive of subsequent mortality among lung transplant recipients.

11 s known to have suboptimal immunogenicity in transplant recipients.

12 mised individuals, especially in solid-organ transplant recipients.

13 iscontinuation of prednisone (RDP) in kidney transplant recipients.

14 bodies (dnDSA) may cause graft loss in renal transplant recipients.

15 dian age was 58 years; 9 patients (43%) were transplant recipients.

16 tial impacts for the management of cancer in transplant recipients.

17 e 10 donors using the Scientific Registry of Transplant Recipients.

18 a (NPC), and lymphomas that develop in organ transplant recipients.

19 ents with end-stage renal disease and kidney transplant recipients.

20 second leading cause of graft loss in kidney transplant recipients.

21 nd risk determinants of PTLD in Irish kidney transplant recipients.

22 loped and validated for the UK population of transplant recipients.

23 V and urothelial carcinogenesis among kidney transplant recipients.

24 ere obtained from the Scientific Registry of Transplant Recipients.

25 mmon single cause of death observed in organ transplant recipients.

26 ed but uncommon complications in solid organ transplant recipients.

27 development of malignant neoplasms in kidney transplant recipients.

28 c immunosuppressants, such as tacrolimus, in transplant recipients.

29 the patient with JCPyVAN and in stable renal transplant recipients.

30 ded a DBD comparison group comprising 23 609 transplant recipients.

31 ith inferior graft outcomes among intestinal transplant recipients.

32 formulations of an immunosuppressive drug in transplant recipients.

33 ins the leading cause of mortality in kidney transplant recipients.

34 association of NTM with mortality among lung transplant recipients.

35 nct immunosuppressive therapy in solid organ transplant recipients.

36 iated with adverse outcomes in stable kidney transplant recipients.

37 ut their association with outcomes in kidney transplant recipients.

38 h advanced chronic kidney disease and kidney transplant recipients.

39 antibodies (non-HLAabs) were screened in 29 transplant recipients.

40 portant causes of morbidity and mortality in transplant recipients.

41 erall, PH was documented in 117 (39%) of 300 transplant recipients.

42 d with the waitlist including KDPI 0% to 85% transplant recipients.

43 ocompromised patients and particularly organ transplant recipients.

44 dence of rejection in HIV-to-HIV solid organ transplant recipients.

45 ascular and kidney outcomes in stable kidney transplant recipients.

46 ntially contribute to allograft damage among transplant recipients.

47 rvival in allogeneic hematopoietic stem cell transplant recipients.

48 f antibody-mediated rejection in solid organ transplant recipients.

49 th increased risk of SCC of the skin in lung transplant recipients.

50 mpact of pretransplant sensitization on lung transplant recipients.

51 relates with delayed graft function in renal transplant recipients.

52 ssessing the risk of BKV infection in kidney transplant recipients.

53 odgkin lymphoma (NHL) in 288 029 solid organ transplant recipients.

54 ontrol in allogeneic hematopoietic stem cell transplant recipients.

55 Pneumocystis pneumonia prophylaxis in renal transplant recipients.

56 and are capable of inducing AML in serially transplanted recipients.

57 nocardiosis (16.2%, 19/117) than in control transplant recipients (1.3%, 3/233, P < .001).

58 3A5, ABCB1, and PXR) were analyzed in kidney transplant recipients (1995-2005, Leiden cohort, n = 153

59 ntified all adult (>/=18 years) first kidney transplant recipients (1996-2011) with ESRD attributed t

60 We reported 47 solid organ transplant recipients (41 kidneys) with cryptosporidiosi

61 The study cohort included 8026 organ transplant recipients, 5224 men (65.1%), with a mean age

62 ctive clinical study including healthy heart transplant recipients 6 months to 25 years of age presen

63 re 13 trials (n = 9850) that included kidney transplant recipients (6 trials), patients who had stage

64 identify the optimal DAA regimen for kidney transplant recipients, accounting for efficacy, timing r

65 diatric and adolescent deceased donor kidney transplant recipients aged 21 years or younger using Aus

66 hour everolimus (EVL) PK in 16 elderly renal transplant recipients (all whites; 10 men; mean age, 64

67 immunocompromised individuals such as organ transplant recipients, although the mechanism remains un

68 ntation, GTD requires genotyping of both the transplant recipient and donor.

69 one case of TMAT, which occurred in a liver transplant recipient and resulted in death from bleeding

70 e longitudinal study, we enrolled 168 kidney transplant recipients and 69 matched donors.

71 er (PTLD) is a serious complication in organ transplant recipients and is most often associated with

72 Diabetes is prevalent among solid organ transplant recipients and is universal among islet trans

73 transplant centers to maintain contact with transplant recipients and obtain necessary follow-up inf

74 Transplant recipients and other immunocompromised hosts

75 but their effects on fractures and safety in transplant recipients and others with CKD are unclear.

76 obtained from a new cohort of tolerant renal transplant recipients and those from age- and sex-matche

77 ents (renal transplant recipients, stem cell transplant recipients, and congenitally infected childre

78 g-term hematopoietic stem cells in secondary transplant recipients, and enhanced survival of mice aft

79 in healthy, immunocompetent individuals, in transplant recipients, and in PTLD patients.

80 clusion, PCNSL risk is highly elevated among transplant recipients, and it carries a poor prognosis.

81 is reactivated in approximately 20% of renal transplant recipients, and it may rarely cause JCPyV-ass

82 ome, the current literature on the virome in transplant recipients, and near-future applications of s

83 in both allografts and urine of human kidney transplant recipients, and unilateral IRI in mice induce

84 This study provides novel evidence that transplant recipients are able to mount significant cros

85 Approximately only 50% of renal transplant recipients are alive at 10 years due to the t

86 Solid organ transplant recipients are at increased risk for developi

87 of chronic hepatitis C virus in solid organ transplant recipients are limited.

88 Approximately 200 000 kidney transplant recipients are living in the United States; t

89 Thirty percent of kidney transplant recipients are readmitted in the first month

90 Transplant recipients are treated with immunosuppressive

91 traded so that sicker patients, that is, SLK transplant recipients, are afforded access to the organ.

92 Pediatric liver transplant recipients arguably have the most to gain and

93 to differentiate between these 2 entities in transplant recipients as well.

94 NETs in 103 consecutive pediatric allogeneic transplant recipients at day 0, +14, +30, +60, and +100.

95 ximately 800 patients in the cohort of renal transplant recipients at our institution, 15 subjects we

96 rom 4 isolated intestine and 3 multivisceral transplant recipients at the time of any operative resec

97 performed between 1998 and 2014 from kidney transplant recipients at the University of Maryland Medi

98 servational study of 1996 adult first kidney transplant recipients between 1991 and 2010 in the Repub

99 a were collected from 1799 consecutive liver transplant recipients between January 1, 2002, and Decem

100 healthy volunteers may not reflect those in transplant recipients, bioequivalence between generic an

101 increased risk of graft loss in adult kidney transplant recipients but the association remains incons

102 ft survival between obese and nonobese liver transplant recipients, but obesity presents important me

103 al population and in HCV-monoinfected kidney transplant recipients, but there are no data to guide it

104 ent of squamous cell carcinoma (SCC) in lung transplant recipients, by attempting to account for impo

105 ctivation of human cytomegalovirus (HCMV) in transplant recipients can cause life-threatening disease

106 Melanoma risk factors and incidence in renal transplant recipients can inform decision making for bot

107 uld significantly advance personalized liver transplant recipient care and management of immunosuppre

108 nd analysis of alloreactive T and B cells in transplant recipients critical for understanding mechani

109 e integrated national Scientific Registry of Transplant Recipients data (1987-2015) with records from

110 Using Scientific Registry of Transplant Recipients data from June 2013 to June 2015,

111 re analyzed using the Scientific Registry of Transplant Recipients data set.

112 We used Scientific Registry of Transplant Recipients data to compare patients listed wi

113 ys, we used 2010-2014 Scientific Registry of Transplant Recipients data to identify 104 998 adult tra

114 ohort study using the Scientific Registry of Transplant Recipients database from 2003 to 2015.

115 ients recorded in the Scientific Registry of Transplant Recipients database who received a first dece

116 of PTTB and may show delayed onset in renal transplant recipients due to the use of lower doses of i

117 s isolates and airway samples from a CF-lung transplant recipient during two years, and followed the

118 In young kidney transplant recipients, elevated ABP is frequently unreco

119 profiling in 318 serum samples from 69 liver transplant recipients enrolled in the Immune Tolerance N

120 transplant history from 977 prevalent kidney transplant recipients enrolled in the Malnutrition-Infla

121 donor-specific antibodies (dnDSA) in kidney transplant recipients, especially in those with stable g

122 Organ-transplant-recipients exhibit cancerization of the skin

123 Non-Hispanic black kidney transplant recipients experience a substantial disparity

124 Black kidney transplant recipients experience disproportionately high

125 contains a rich set of data on United States transplant recipients, follow-up data may be incomplete.

126 Kidney transplant recipients, for example, have a 7-fold risk o

127 Ninety-three transplant recipients from 2 Australian transplant units

128 076 adult Medicare-primary first-time kidney transplant recipients from December 1999 to October 2011

129 t survival was significantly worse for liver transplant recipients from donors with ITP compared with

130 nts from donors with ITP compared with liver transplant recipients from donors without ITP (64% vs. 8

131 transplant (KT), and dual liver kidney (DLK) transplant recipients from the Hepatitis C Therapeutic R

132 . hominis infections were identified in lung transplant recipients from the same thoracic intensive c

133 ational data registry used a cohort of renal transplant recipients from the United States Renal Data

134 Transplant recipients had elevated incidence for PCNSL c

135 Renal transplant recipients had greater risk of developing mel

136 The risk of graft failure in young kidney transplant recipients has been found to increase during

137 e proportion of elderly patients among renal transplant recipients has increased, pharmacokinetic (PK

138 Lung transplant recipients have an increased risk for infecti

139 rrow therapeutic index immunosuppressants in transplant recipients have been lacking.

140 Solid organ transplant recipients have increased risk for developing

141 We analyzed a prospective cohort of renal transplant recipients having routine EBV PCR surveillanc

142 Centers with >30% of their liver transplant recipients hospitalized >/=30 days in the fir

143 rovecii pneumonia (PCP) occurred among heart transplant recipients (HTR) at the outpatient clinic of

144 A previous GWAS performed in 300 renal transplant recipients identified two SNPs (rs3811321 and

145 In 2014, Scientific Registry of Transplant Recipients implemented new Bayesian methodolo

146 A renal transplant recipient in her 60s presented with a history

147 ta System records of Medicare-insured kidney transplant recipients in 2000 to 2011 to determine clini

148 cribe the results of 11 ABOi pediatric renal transplant recipients in the 2 largest centers in the Un

149 ecome clinically useful surrogates in kidney transplant recipients, including functional T cell assay

150 mbolic events across a wide variety of liver transplant recipients, including those at low risk of bl

151 The care of kidney transplant recipients involves a balance between maximiz

152 f IL-2RAb in pediatric and adolescent kidney transplant recipients is associated with at least a 40%

153 current immunosuppressive therapy in kidney transplant recipients is effective, dosing is convention

154 hepatitis C virus (HCV) infection in kidney transplant recipients is limited because of the risk for

155 f hepatitis C virus (HCV) infection in renal transplant recipients is possible, but limited data exis

156 al maintenance dose of tacrolimus for kidney transplant recipients is unknown.

157 but the optimal vaccination schedule in lung transplant recipients is unknown.

158 the risk of acute rejection in adult kidney transplant recipients is well established, a similar ben

159 kidney injury (AKI) occurred in four kidney transplant recipients (KDIGO grade 1: n = 3, grade 3: n

160 Consequently, for transplant recipients, killing latently infected cells c

161 hemodialysis treatment (CKD 5D) and 8 kidney transplant recipients (KT) with severe aortic valve sten

162 (PVAN) after BK virus reactivation in kidney transplant recipients (KTR) can compromise graft surviva

163 ted with baseline viral serostatus in kidney transplant recipients (KTR) on sirolimus have not been w

164 etry is used to assess bone health in kidney transplant recipients (KTR).

165 CMV infection in kidney transplant recipients (KTRs) has been associated with an

166 -specific T cells in CMV-seronegative kidney transplant recipients (KTRs) have been attributed to an

167 ection and improves graft outcomes in kidney transplant recipients (KTRs).

168 knockout mice, we demonstrate that stem cell transplant recipients lacking the ability to generate or

169 icularly within African American (AA) kidney transplant recipients; little is known about intrapatien

170 In lung transplant recipients (LTRs), human cytomegalovirus (HCM

171 development of AR and BOS in pediatric lung transplant recipients (LTxR).

172 Operationally tolerant pediatric liver transplant recipients maintain generally stable allograf

173 en reported in ABO-incompatible (ABOi) renal transplant recipients managed solely with antibody remov

174 and the common occurrence of GI disorders in transplant recipients may delay diagnosis of GITB.

175 Overall, 10649 organ transplant recipients (mean [SD] age, 51 [12] years; 387

176 the results in a cohort of 10 stable kidney transplant recipients (median of 4.3 years posttransplan

177 in the peripheral blood and AMR, 715 kidney transplant recipients (median, 6.3 years posttransplanta

178 t bisphosphonates may slow loss of BMD among transplant recipients (moderate SOE), but their effects

179 Pre- and postvaccination sera from kidney transplant recipients (n = 60) immunized with the 2012-2

180 risk factors from the Scientific Registry of Transplant Recipients (n = 74,859) and tested whether (1

181 Thus, immunosuppressive strategies for lung transplant recipients need to be tailored based on the u

182 re survival case of isolated GITB in a renal transplant recipient, occurring seven years after transp

183 t appear to adversely affect the outcomes of transplant recipients of concomitantly recovered solid o

184 Kidney transplant recipients often receive antibody induction.

185 l population, it is possible that either the transplant recipient or donor may act as the source of v

186 Organ transplant recipients (OTRs) have a 100-fold increased r

187 increased risk of skin cancer in solid organ transplant recipients (OTRs), no study has estimated the

188 r has been well characterized in white organ transplant recipients (OTRs); however, most patients on

189 r on organ donation and utilization, as well transplant recipient outcomes.

190 VEC proliferation than those from syngeneic transplant recipients (P = 0.03).

191 ded all adults in the Scientific Registry of Transplant Recipients placed on the heart transplant act

192 Three lung transplant recipients presented with invasive M. hominis

193 PRM is a novel imaging tool for lung transplant recipients presenting with spirometric declin

194 In the Spare-the-Nephron (STN) Study, kidney transplant recipients randomized about 115 days posttran

195 In the United States, 5% of adult liver transplant recipients receive a graft donation after cir

196 In this cohort of de novo kidney transplant recipients receiving tacrolimus and prednison

197 pective randomized study in which 288 kidney transplant recipients receiving tacrolimus and prednison

198 We prospectively monitored 617 heart transplant recipients referred from 4 French transplant

199 Transplant recipients regarded graft loss as worse than

200 Still, the risk of SCC in organ transplant recipients remains much higher than in the ge

201 Scientific Registry of Transplant Recipients report cards of US organ transplan

202 r Pneumocystis pneumonia prevention in renal transplant recipients, reported adverse drug reactions m

203 6.6%, 94.5%, and 90.9% among LT, KT, and DLK transplant recipients, respectively.

204 m(2) among deceased and living donor kidney transplant recipients, respectively.

205 was efficacious and safe in LT, KT, and DLK transplant recipients; ribavirin did not influence SVR,

206 doxal 5'-phosphate (PLP) are common in renal transplant recipients (RTRs) and confer increased risk o

207 tions of pyridoxal-5-phospate (PLP) in renal transplant recipients (RTRs).

208 ted with an increased risk of death in renal transplant recipients (RTRs).

209 ght the need to tailor interventions to each transplant recipient's unique needs, motivations, and ba

210 In prevalent kidney transplant recipients, serum TNF-alpha and IL6 were inde

211 nical trial, we randomized 90 de novo kidney transplant recipients shortly after transplantation to e

212 of voriconazole use when prescribed to lung transplant recipients should be carefully weighed versus

213 domized phase III study of 719 de novo liver transplant recipients showed that early everolimus plus

214 De novo solid organ transplant recipients (SOTR) have a steep learning curve

215 Solid organ transplant recipients (SOTR) with a pretransplant malign

216 effectiveness is not optimal in solid organ transplant recipients (SOTR).

217 DNA-positive plasma samples from solid-organ transplant recipients (SOTRs) were tested.

218 or to morbidity and mortality in solid organ transplant recipients (SOTRs).

219 time period from the Scientific Registry of Transplant Recipients (SRTR; n=13 717).

220 Our data indicate that elderly renal transplant recipients starting EVL 1 month after transpl

221 tments from 20 HCMV-infected patients (renal transplant recipients, stem cell transplant recipients,

222 Our study included 86 DSA+ kidney transplant recipients subjected to protocol biopsy, who

223 rus (BKV) in urinary tract cancers in kidney transplant recipients, suggesting that BKV could contrib

224 icantly prolonged survival compared with MAC-transplanted recipients (TBI of 850 cGy plus cyclophosph

225 tial group of donors are those who have been transplant recipients themselves, or Organ Donation Afte

226 sted on >1000 samples from a cohort of renal transplant recipients to assess its performance in a cli

227 teriaceae and CRE carriage among solid organ transplant recipients to inform management of this vulne

228 y score matched cohort study of adult kidney transplant recipients transplanted between May 1, 2001,

229 e cohort study of 2749 adult Norwegian renal transplant recipients, transplanted between 1999 and 201

230 of 265 consecutive chronic hepatitis B liver transplant recipients treated with entecavir monotherapy

231 se, we describe the largest series of kidney transplant recipients treated with prophylactic eculizum

232 tial for loss of stability of these cells in transplant recipients treated with TAC based immunosuppr

233 In this retrospective study of US kidney transplant recipients undergoing PCI, DES was associated

234 Longitudinal cohort study of kidney transplant recipients using a data set created by linkin

235 assessed among 118,440 Caucasian solid organ transplant recipients using multivariate Cox regression

236 Whether outcomes of MI differ among renal transplant recipients vs patients with stage 5D CKD or t

237 of ST-segment elevation MI (STEMI) in renal transplant recipients vs the stage 5D CKD group or the n

238 ab to prevent bone loss in first-year kidney transplant recipients was associated with more frequent

239 Using data from the Scientific Registry of Transplant Recipients, we compared outcomes for all SLK

240 s organization to the Scientific Registry of Transplant Recipients, we identified 15 125 hemodialysis

241 Forty kidney transplant recipients were 1:1 randomized to belatacept

242 In the phase II IM103-100 study, kidney transplant recipients were first randomized to belatacep

243 A total of 5983 renal transplant recipients were included.

244 Nine hundred lung transplant recipients were included.

245 Data from the Scientific Registry of Transplant Recipients were linked to IMS pharmacy fills

246 Medical records of the donor and infected transplant recipients were reviewed for clinical charact

247 A total of 2050 liver transplant recipients were studied, of these 960 (46.8%)

248 trols receiving corticosteroids in pediatric transplant recipients which reported growth as change in

249 n by linking the U.S. Scientific Registry of Transplant Recipients, which includes data on keratinocy

250 e-center retrospective analysis of 207 liver transplant recipients who achieved MELD score of 40 or h

251 art, 34 liver, 79 kidney, and 5 liver-kidney transplant recipients who completed treatment for an epi

252 ne risk factors and characteristics of renal transplant recipients who develop melanoma.

253 We retrospectively identified 59 renal transplant recipients who developed dnDSA and had serum

254 Adult renal transplant recipients who had symptomatic chronic norovi

255 skin cancer after retransplantation in organ-transplant recipients who have already developed posttra

256 crossmatch positive living donor HLAi kidney transplant recipients who received their transplant betw

257 uantified the circulating ApoL1 in two liver transplant recipients whose native APOL1 genotype differ

258 tcomes have not improved, and nearly half of transplant recipients will lose their allografts by 10 y

259 oven regression of liver fibrosis in a liver transplant recipient with cirrhosis after chronic HEV in

260 We report our experience treating 43 renal transplant recipients with 4 different DAA regimens.

261 A cohort of 596 renal transplant recipients with 50,011 serial tacrolimus trou

262 Kidney transplant recipients with a pretransplant cancer had a

263 In a cohort of 242 kidney transplant recipients with acute allograft dysfunction,

264 Twelve renal transplant recipients with aHUS-related end-stage renal

265 y was reviewed for adult living donor kidney transplant recipients with BMI of 40 kg/m or greater per

266 Organ transplant recipients with CF should initiate CRC screen

267 Forty-four DSA-positive kidney transplant recipients with characteristic ABMR morpholog

268 free regimen ledipasvir-sofosbuvir in kidney transplant recipients with chronic genotype 1 or 4 HCV i

269 Treatment-naive or -experienced kidney transplant recipients with chronic genotype 1 or 4 HCV i

270 Additionally, among 109 heart or kidney transplant recipients with CKD, those with higher serum

271 Thirteen kidney transplant recipients with complicated UTIs underwent bo

272 Our results suggest that transplant recipients with cutaneous SCC, but not BCC, h

273 We identified 45 kidney transplant recipients with dnDSA detected between Januar

274 In 42 kidney transplant recipients with functioning grafts who had re

275 Eighteen percent (3/17) of lung transplant recipients with ganR-CMV had received <6 week

276 hort course (in hospital only) HBIG in liver transplant recipients with HBV DNA less than 100 IU/mL p

277 ve an acceptable safety profile among kidney transplant recipients with HCV genotype 1 or 4 infection

278 ined percentages of new waitlist members and transplant recipients with HCV infection, stratified by

279 The outcome of 149 transplant recipients with HEHE recorded in the European

280 RM(PD)) were compared between bilateral lung transplant recipients with irreversible spirometric decl

281 m 1 patient with JCPyVAN and 20 stable renal transplant recipients with JCPyV viruria was attempted.

282 immunodeficiency virus/HCV coinfected kidney transplant recipients with ledipasvir-sofosbuvir at our

283 k in healthy pediatric and young adult heart transplant recipients with minimal risk when low initial

284 s on average 11-fold (P = 0.002) higher than transplant recipients with no AMR and 24-fold (P = 0.008

285 Renal transplant recipients with otherwise unexplainable chron

286 However, in pediatric heart transplant recipients with PRA greater than 50% or conge

287 not death-censored renal graft loss in renal transplant recipients with PTDM.

288 s reaffirm the need for careful selection of transplant recipients with PTM.

289 gs in the current study indicate that kidney transplant recipients with PV replication and smoking ar

290 he incidence of such complications among HPC transplant recipients with sickle cell disease.

291 In-hospital mortality rates in renal transplant recipients with STEMI are more favorable comp

292 Among renal transplant recipients with STEMI, the use of reperfusion

293 Kidney transplant recipients with urinary angiogenin amounts in

294 trial, 152 treatment-naive adult solid organ transplant recipients, with CD20(+) PTLD unresponsive to

295 found in urine samples from 19 stable renal transplant recipients, with JCPyV quasispecies detected

296 tored normal physiological functions in this transplant recipient without major complications in the

297 athymic interleukin-22 (IL-22) compared with transplant recipients without GVHD, thereby inhibiting I

298 rm treatment with ribavirin is safe in liver transplant recipients, without achieving HEV sustained v

299 ion suggest that routine cancer screening in transplant recipients would allow for earlier diagnosis

300 Among first kidney transplant recipients younger than 30 years in France, t